Publicacións en colaboración con investigadores/as de Poznan University of Medical Sciences (4)

2023

  1. A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)

    Vaccine, Vol. 41, Núm. 21, pp. 3387-3398

2017

  1. Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial

    The Lancet Infectious Diseases, Vol. 17, Núm. 1, pp. 58-67

2015

  1. 13-Valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants

    Pediatrics, Vol. 135, Núm. 4, pp. e876-e886

2012

  1. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: A randomised, single-blind, placebo-controlled, phase 2 trial

    The Lancet Infectious Diseases, Vol. 12, Núm. 8, pp. 597-607